Senolytic compounds reduce epigenetic age of blood samples in vitro

  • NPJ Aging. 2025 Feb 4;11(1):6. doi: 10.1038/s41514-025-00199-z.
Vithurithra Tharmapalan  1  2 ,  Miriam Du Marchie Sarvaas  1  2 ,  Michael Bleichert  1  2 ,  Martina Wessiepe  3 ,  Wolfgang Wagner  4  5  6
Affiliations
  • 1. Institute for Stem Cell Biology, RWTH Aachen University Medical School, 52074, Aachen, Germany.
  • 2. Helmholtz-Institute for Biomedical Engineering, RWTH Aachen University Medical Faculty, 52074, Aachen, Germany.
  • 3. Institute for Transfusion Medicine, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
  • 4. Institute for Stem Cell Biology, RWTH Aachen University Medical School, 52074, Aachen, Germany. [email protected].
  • 5. Helmholtz-Institute for Biomedical Engineering, RWTH Aachen University Medical Faculty, 52074, Aachen, Germany. [email protected].
  • 6. Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Cologne, Germany. [email protected].
PMID: 39905063 DOI: 10.1038/s41514-025-00199-z
Abstract

Senolytic drugs raise the expectation that they can specifically eliminate a subset of senescent cells in a given tissue. In this study, we have exemplarily analyzed if a 3-day treatment of human blood samples in vitro would reduce age-associated biomarkers, with a particular focus on epigenetic age-predictions. Of eight tested compounds, JQ1, RG7112, nutlin-3a, and AMG232 reduced epigenetic age, indicating that this approach may be useful in drug screening for senolytic compounds.

Products